You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

Guidelines & Advice

About Guidelines Email Guidelines Team

Radiopharmaceuticals

The guidelines and other documents available here provide recommendations related to radiopharmaceuticals for people affected by cancer in Ontario.

Displaying Guidelines

11 Items

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Document Status: Current
ID: GL END 5-7
Version: 3

Nov 2021

Endorsement of the 2018 American Society of Clinical Oncology Treatment of Malignant Pleural Mesothelioma Guideline

Document Status: In-Review
ID: 7-14
Version: 3

Dec 2018

Ibritumomab Tiuxetan in Lymphoma

Document Status: Archived
ID: 6-17

Nov 2013

Iodine-131 Tositumomab in Lymphoma

Document Status: Archived
ID: 6-19

Jan 2007

Oncology Caregiver Support Framework

Document Status: Current
ID: N/A
Version: N/A

Oct 2019

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Document Status: Current
ID: GL-END 3-25

Nov 2023

Position Statements for Nursing Practice in Cancer Care

Document Status: Current
Version: 2

May 2021

Radionuclide Therapy for Neuroendocrine Malignancies

Document Status: Current
ID: 12-13

Aug 2011

Radionuclide Therapy for Patients with Neuroendocrine Tumors (NETs) in Ontario: Expert Panel Report

Document Status: Current
ID: GL-C50-01

Jan 2011

Recommendations for the Delivery of Psychosocial Oncology Services in Ontario

Document Status: Current

Apr 2018

Systemic therapy for unresectable advanced or metastatic pancreatic and midgut neuroendocrine tumours

Document Status: Current
ID: GL 2-21
Version: 2

Mar 2024